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ABSTRACT
Purpose: Healthcare workers have a main role in
detection, assessment and spontaneous reporting of
adverse drug reactions (ADRs), and improvement of
their related knowledge, attitude and perception is
essential. The goal of this study was evaluation of
clinical pharmacists’ interventions in improvement of
knowledge, attitude and perception of healthcare
workers about ADRs in a teaching referral hospital,
Tehran, Iran.
Method: Changes in knowledge, attitude and
perception of healthcare workers of Imam teaching
hospital about ADRs were evaluated before and after
clinical pharmacists’ interventions including
workshops, meetings and presentations.
Results: From the 100 participated subjects, 82 of
them completed the study. 51% of the health workers
have been aware of the Iranian Pharmacovigilance
Center at the ministry of health before intervention and
after that all the participants knew this centre. About
awareness and detection of ADRs in patients, 69
(84.1%) healthcare workers recognised at least one,
and following interventions, it was improved to 73
(89%). Only seven (8.5%) subjects have reported
ADRs in before intervention phase that were increased
significantly to 18 (22%) after intervention.
Conclusion: Clinical pharmacists’ interventions were
successful in improvement of healthcare workers’
knowledge, attitude and perception about ADRs and
spontaneous reporting in our hospital.
INTRODUCTION
Adverse drug reactions (ADRs) are a major
cause of morbidity and mortality around the
world and have high economic burden on
healthcare systems.1e3 Pharmacovigilance
studies are more important for evaluating
medication safety following drugs
marketing.4 Healthcare workers, especially
medical practitioners, are the principal
contributors of ADR reports.5 Healthcare
professionals’ knowledge, attitudes and
perceptions about ADR have central role in
improvement of patients’ safety.1 5 6 There
are some concerns about ADR spontaneous
reporting by healthcare workers, including
ADR importance, do not know how to report
and fill the yellow cards, doubt about adverse
effect and suspicious drug, lack of time, fear
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of legal problems, avoiding paper works and unavailable
yellow card.1 5e7 WHO standards show that the best
spontaneous reporting rate is over 200 reports per
1 000 000 populations per year. Consequently, in Iran
with a population of over 70 million, it is expected to
have at least 14 000 reports per year that unfortunately
only 4967 reports per year were sent to the Iranian
Pharmacovigilance Center (IPC).6
Continuous education of healthcare workers about
pharmacovigilance by oral presentations, verbal
reminders, providing ADR newsletters by email, mailing
and direct distribution for hospital staff, advertisement,
increased accessibility of yellow cards, attending of
pharmacist in the medical wards and involving actively in
education and training of healthcare workers especially
nurses and physicians were proposed for improvement
of knowledge and attitude of heathcare workers about
ADRs.8e10
The goal of this study was evaluation of clinical phar-
macists’ interventions in improvement of knowledge,
attitude and perception about ADRs in a referral
teaching hospital, Tehran, Iran.
METHOD
In this study, changes in knowledge, attitude (perspec-
tive towards ADR and way of saying and doing about
that) and perception (awareness or understanding of
the ADR) of healthcare workers of the Imam Khomeini
Complex Hospital (a tertiary referral hospital with 1200
beds that is affiliated to Tehran University of Medical
Sciences, Tehran, Iran) about ADRs were evaluated
before and after clinical pharmacists’ interventional
study. Based on WHO definition, ADR was considered as
any noxious, unintended and undesired effect of a drug
that occurs at doses used in humans for prophylaxis,
diagnosis or therapy. To assess knowledge, attitude and
perception of healthcare workers about ADR, a validate
questionnaire1 was used. The questionnaire consisted of
a total of 15 questions (five questions for each of the
knowledge, attitude and perception). Multiple-choice
questions about ADR definition, goals and importance
of pharmacovigilance and types of drug-induced reac-
tions that must be reported were used for evaluation of
the participants’ knowledge. For evaluation of attitude
and perception, some cases with drug-induced ADRs
were designed and asked from the participants to
determine which of them must be reported.
In the first phase of the study, the clinical pharmacists
(three persons) attended in different medical wards of
the hospital and invited from all healthcare workers
(medical students, nurses, physicians and pharmacist) to
participate in the study. From whom those had enough
time and were happy with our programme schedule
asked to fill the questionnaire. Then, the participants
were invited to attend in an educational programme
(clinical pharmacists’ interventions) in the hospital.
Clinical pharmacists’ interventions included training
workshops (providing lectures and group discussion,
3 h/week for four consecutive weeks) and continuously
providing information at the hospital morning case
report section (every other day for 1 month) about ADR
importance, seriousness, preventability, necessity of
reporting and spontaneous reporting system and its
advantages. In the workshop, they learnt to fill a yellow
card and emphasised on reporting any suspected reac-
tion regardless of uncertainty about the causality. After
3 months, the same questionnaire was filled again by the
participants in the educational programmes. Effects of
clinical pharmacists’ interventions in improvement of
knowledge, attitude and perception of the participants
about ADR were evaluated by comparing their responses
to the questions before and after interventions. All data
were analysed by Statistical Package for Social Sciences
(SPSS) software V.16.0. Results were reported as
frequency, and for comparing the before and after
intervention’s results, we used cross tabulation and c2
test. Values <0.05 were considered as significant.
RESULTS
From 136 healthcare workers that were positive for our
invitation, only 100 persons attended in the educational
programmes regularly and from them 82 questionnaires
Table 1 Reasons that cause ADR not be reported
Reason Before intervention After intervention p Value
Uncertain association between reaction and drug 18 (22) 17 (20.7) 1
Unimportant to report 13 (15.9) 11 (9) 0.30
Well known that do not need to be reported 21 (25.6) 16 (19.5) 0.23
Unaware of the existence of a national ADR reporting system 17 (20.7) 15 (18.3) 0.62
Did not know importance of reporting 12 (14.6) 10 (12.2) 0.69
Did not know how to report 20 (24.4) 12 (14.6) 0.02
Lack of time 11 (13.4) 16 (19.50) 0.18
Lack of financial reimbursement 2 (2.4) 2 (2.4) 1
Fear of legal liability 2 (2.4) 2 (2.4) 1
Yellow card not available 16 (19.5) 9 (11) 0.04
Reporting system is too technical 18 (9.8) 14 (4.9) 0.12
Not enough information from the patient 82 (100) 3 (3.7) 0.0001
ADR, adverse drug reaction.
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were filled out both before and after intervention with
same name. The questionnaires that were filled only in
one phases of the study were excluded. Thirty-five men
and 47 women including 7 (8.5%) physicians, 31
(37.8%) residents, 26 (31.7%) interns, 17 (20.7%)
nurses and 1 (1.2%) pharmacist participated in the
study. We had not any intention to invite senior or junior
of the wards and based on the demographic data of the
study we had participants from the both groups. Average
age of the participants was 30.9 years with SD of
6.7 years.
Fifty-one per cent (n¼42) of the healthcare workers
were aware of the IPC at Iranian ministry of health
before interventions and after that all the participants
knew this centre. Four people (4.9%) had attended in an
ADR workshop prior to this study. Sixty-nine (84.1%)
subjects had recognised at least one ADR before, and
following interventions, 73 (89%) cases have identified
ADR. Only seven (8.5%) people have reported ADR
before intervention that was increased significantly to 18
(22%) by the interventions (p<0.001).
One of the question was designed to determine centre
that ADRs were reported previously by the participants.
Two (2.4%) responders had sent the ADR reports to the
IPC in Tehran, one (1.2%) to the Food and Drug
Organization in another city of Iran, one (1.2%) to the
manufacture and four (4.9%) to hospital’s ADR canter
before the interventions and after that reporting to the
IPC increased to 17 (20.7%) cases (p<0.001).
Doubt about occurrence of an ADR did not alter with
the interventions significantly (63.4% vs 69.5%).
Reasons that caused the participants did not report ADR
are shown in table 1. The interventions had considerable
impact to reduce causes of under-reporting, including
did not know how to report (p¼0.002), yellow card not
available (p¼0.039) and lack of enough information
about the patient (p<0.0001).
All types of ADR that might promote healthcare
professionals for reporting them were improved signifi-
cantly after clinical pharmacists’ interventions (table 2).
The next questions were about healthcare workers’
perception about ADR and spontaneous ADR reporting
goals. As it is indicated in table 3, our interventions had
a significant effect on the participants’ total perception
about ADR spontaneous reporting.
Responders’ perception about spontaneous reporting
was not improved significantly following the clinical
pharmacists’ interventions (table 4). Fifty-five (67.1%)
and 60 (73.2%) subjects believed that it is a professional
responsibility at pre- and post-interventional phases of
the study, respectively.
Regarding the participants’ attitude for reporting
ADRs, the question was, in which of the fallowing
conditions (carbamazepine-induced agranulocytosis,
hypoglycaemia following use of a new hypoglycaemic
agent, a new statin-induced myalgia, weight loss
following fluoxetine therapy in a young women,
amoxicillin-induced skin rash, pedal oedema following
amlodipine therapy, bronchospasm following use of
new b blocker and a new antiepileptic-induced paraes-
thesia) you will fill the yellow card? Only reporting of
serious reactions such as carbamazepine-induced
agranulocytosis was improved by clinical pharmacists’
interventions.
The participants’ preferred systems to report an ADR
have been indicated in table 5. Yellow card, online,
telephone and fax were frequently preferred methods
for ADRs reporting in this study, respectively (table 6).
Table 2 Reaction characteristics that might encourage healthcare professionals to report
Factor Before intervention After intervention p Value
A serious reaction 53 (64.6) 74 (90.2) <0.001
Unusual reaction 38 (46.3) 66 (80.5) <0.001
Reaction of a new product 36 (43.9) 46 (56.1) 0.02
Reaction not reported before for a particular drug 36 (43.9) 66 (80.5) <0.001
Reaction is well recognised for a particular drug 8 (9.8) 31 (37.8) <0.001
Any reaction (serious or non-serious, well known or new)
to an old or new product
7 (20.7) 26 (31.7) 0.004
Table 3 Healthcare workers’ perception about ADR and spontaneous reporting systems’ goals, before and after intervention
Goal Before intervention After intervention p Value
To enable safe drugs to be identified 36 (43.9) 46 (56.1) 0.02
To measure the incidence of ADR 39 (47.6) 57 (69.5) <0.001
To identify factors which might predispose to ADR 35 (42.7) 58 (70.7) <0.001
To identify previously unrecognised ADRs 56 (68.3) 70 (85.4) <0.001
To compare ADRs for drugs in similar therapeutic classes 36 (43.9) 52 (63.4) <0.001
To compare ADRs of same drug from different drug companies 44 (53.7) 44 (53.7) 1
ADRs, adverse drug reactions.
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DISCUSSION
To the best of our knowledge, this is the first survey in
Iran that have evaluated clinical pharmacists’ interven-
tions in improvement of the healthcare workers’
knowledge, attitudes and perceptions regarding ADR.
Our results showed that 91.5% of healthcare workers
of our hospital that participated in the study never
reported any ADR and 49% of them were not even aware
of the IPC at the first phase of the study and obviously
improved after interventions. Iranian pharmacists are
more aware about the IPC6 that may be related to
pharmacists’ more education about drugs’ safety.
Before the clinical pharmacists’ interventions, a little
(2.4%) of the responders sent ADR reports to the IPC at
the ministry of health and after that all the reports have
set to this centre. It shows that interventions improve
participant information regarding the centre that is
responsible for analysing and managing of their reports.
In previous research in Shiraz, Iran,1 11% of the reports
were sent to the IPC.
The considerable numbers of healthcare workers in
the present study never reported an ADR that is
comparable with other studies.4 6 11 In the first phase of
the study, the main reasons of under-reporting of ADR
were in order of had not enough information from the
patient, too well known to report, did not know how to
report, uncertain association and being unaware of the
existence of a national ADR reporting system.
Although there are many studies12e18 that assess some
causes of under-reporting ADR, a little of them have
evaluated these barriers in hospitals. Results of a study
performed in a tertiary teaching hospital in Barcelona/
Spain are similar to our study, and lack of time to report
an ADR due to the workload of clinical practitioners was
detected as the most important reason to ADR under-
reporting. Other causes of under-reporting in that study
were lack of information about the spontaneous
reporting system, unavailability of yellow cards, doubt of
ADR causality assessment and lack of patient confiden-
tiality.12 Other reasons for under-reporting of an ADR in
other studies were diagnosed as uncertain association,
too trivial to report, too well known to report, yellow
card unavailability, lack of time and not knowing how to
report.13e18
In the present study, serious and unusual reactions,
unreported ADR before and reactions to a new product
were selected as more important ADR for reporting by
the participants. These are as the same as other studies’
results.4 19e22 We found only one study in that the idea
of reporting all kind of ADRs was more often selected by
Table 4 Believes about spontaneous reporting, before and after intervention
Believes about spontaneous reporting Before intervention After intervention p Value
Professional responsibility 55 (67.1) 60 (73.2) 0.12
Felt that one report cannot modify the healthcare system 6 (7.3) 6 (7.3) 1
All serious ADRs were recognised before drug marketing 3 (3.7) 1 (1.2) 0.5
Completely aware of what should be reported 4 (4.9) 8 (9.8) 0.06
Yellow cards are too complicated 19 (23.2) 18 (22) 1
ADRs, adverse drug reactions.
Table 5 Healthcare workers’ attitude for reporting, some instances of adverse drug reaction
Event Category of reaction
Report before
the intervention
Report after the
intervention p Value
Carbamazepine-induced
agranulocytosis
Serious 30 (36.6) 74 (90.2) <0.001
Hypoglycaemia’s coma of a
new diabetes medication
Serious for a new drug 48 (58.5) 45 (54.9) 0.72
Myalgia with a new statin New drug 19 (23.2) 20 (14.2) 1
Weight loss after 8 weeks of
fluoxetine
Well recognised for a
particular drug
69 (7.3) 13 (15.9) 0.14
Rash with amoxicillin after
6-day treatment
Well recognised for a
particular drug
18 (22) 12 (14.6) 0.33
Foot oedema after 4-month
amlodipine treatment
Well recognised for
a particular drug
19 (23.2) 18 (22) 1
Pain and tingling of tongue
after 2 weeks of a new
anti-seizure therapy
Reaction not reported
before for a particular
drug
33 (40.2) 40 (48.8) 0.34
Bronchospasm in an asthmatic
patient after the first administration
of a b blocker
Serious well recognised
for a particular drug
33 (40.2) 29 (35.4) 0.63
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pharmacist than reporting only serious and unexpected
reactions.23 After the study’s interventions, beliefs of
reporting of all drug-related reactions have been
increased significantly.
Identifying previously unreported ADR was the most
important goal for ADR reporting in before and after the
interventions of the study. This was also reported by
other studies.14 24 Regarding the influence of the clinical
pharmacists’ interventions on modifying healthcare
workers’ perception about ADR, just reporting carba-
mazepine-induced agranulocytosis showed a significant
change, which indicated reporting of a serious reaction.
The preferred method to report an ADR was yellow
card followed by online report in both before and after
the interventions. In previous study in Iran, phone was
the selected method for ADR reporting by pharmacists.1
Our study was a single-centre study with small sample
size and short duration between pre- and post-clinical
pharmacists’ interventions participants’ evaluation. It
seems that the consequence of the interventions will be
pale over time. Another limitation of our survey was
incompletely filled questionnaires that consequently we
could not enrol all 100 questionnaires for the analysis.
Educational programme including workshops, oral
presentations, group discussion, designing ADR news-
letters in hospitals, providing information about phar-
macovigilance for healthcare workers by mail, email,
verbal reminders, advertisement and continuous educa-
tion of nurses, physicians and pharmacists about ADRs,
regular attending of pharmacists in the medical wards
and involving actively in patient’s pharmaceutical care
are essential for improving healthcare workers knowl-
edge, attitudes and perceptions about ADRs.7e10
In conclusion, clinical pharmacists’ interventions can
improve knowledge, attitude and perception of health-
care workers about ADR that is a great issue of impor-
tance regarding pharmacovigilance and public health.
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